Takeda Pharmaceutical
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +38.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 311.0x | Better than 1% |
| Forward P/E | 39.3x | Better than 11% |
| Price / Sales | 2.3x | Better than 52% |
| P/E vs own 5-yr range | 100th pctl | Better than 1% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.8% | Better than 42% |
| Net income CAGR (3Y) | -22.3% | Better than 16% |
| Free cash flow CAGR (3Y) | 22.2% | Better than 67% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 65.1% | Better than 79% |
| Operating margin | 10.3% | Better than 52% |
| Net margin | -3.4% | Better than 21% |
| Return on equity | -2.1% | Better than 26% |
| Return on invested capital | -0.6% | Better than 27% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 19.7% | Better than 96% |
| 6-month return | 34.0% | Better than 91% |
| 12-month return (ex latest month) | 44.0% | Better than 80% |
| Distance below 52-week high | 1.3% | Better than 99% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.1x | Better than 24% |
| Debt to assets | 31.5% | Better than 39% |
| Interest coverage | 0.0x | Better than 25% |
| Free cash flow / net income | 627.8% | Better than 94% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 21.41
- Open
- 21.82
- Day range
- 21.74 - 22.07
- Avg price
- 21.87
- Volume
- 3.80M
- Turnover
- 83.19M
- Turnover ratei
- 0.12%
- Volume ratioi
- 0.98
- Amplitudei
- 1.52%
- 52-week rangei
- 13.92 - 22.07
Valuation
- P/Ei
- -71.85
- P/E (TTM)i
- 311.00
- P/Bi
- 1.50
- EPSi
- -0.30
- Book value / shi
- 14.49
- Net profit
- -970.94M
- Net assets
- 46.44B
Share structure
- Market cap
- 69.76B
- Float capi
- 67.54B
- Shares out
- 3.20B
- Float sharesi
- 3.10B
Dividend & listing
- Div yield (TTM)i
- 1.44%
- Dividend (TTM)
- 0.31
- Listing date
- 1970-01-01
1.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+3.04M net over the window
Short interest
- Shares short
- 3.07M
- % of floati
- 0.10%
- Days to coveri
- 1.02
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Takeda Pharmaceutical (TAK)?
Takeda Pharmaceutical last traded at 21.77. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Takeda Pharmaceutical's market cap?
About 69.76B.
What is the P/E ratio of Takeda Pharmaceutical?
The trailing twelve-month P/E is 311.00, above its own 5-year average of 40.04 — toward the top of its historical range (100.00% percentile). See the Valuation tab for the full history.
Does Takeda Pharmaceutical pay a dividend?
Yes. The trailing dividend yield is 1.44%. The 2025 payout was up 6.9% from 2024. See the Dividends tab for the full payment history.
Is Takeda Pharmaceutical a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 50.46, which implies 131.8% upside from the current price. This is not investment advice.
What is Takeda Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Takeda Pharmaceutical a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Takeda Pharmaceutical discussion 0 comments